CD34

Across TCGA pan-cancer cohorts, CD34 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CD34 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CD34 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CD34 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where CD34 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.488	0.242	.007	39	view →
LUAD	DFS	Tertile	II,III,IV	0.688	0.966	.012	21	view →
CCRCC	DFS	Median	III,IV	0.736	0.434	.010	14	view →
LSCC	DFS	Median	All	0.867	1.000	.003	13	view →
HNSC	OS	Quartile	All	0.795	0.618	.039	6	view →
UCEC	DFS	Median	II,III,IV	0.536	0.880	.044	4	view →
GBM	DFS	Median	All	0.408	0.223	.028	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CD34–PDAC (DFS)

Open the PDAC breakdown →